VGXI, a highly regarded CDMO supporting the gene therapy and DNA vaccine industries, called upon BE&K Building Group to design and build its new greenfield manufacturing facility. The initial phase of the project will quintuple the company’s current production capacity. Located in Deison Technology Park in Conroe, TX, the new headquarters will have two levels providing much needed space for laboratories, purification, filling, packaging, warehousing, and process support. It will also provide measurable office and conference space with associated amenities to accommodate VGXI’s recent and future growth. Multiple manufacturing trains and production suites will be incorporated into this initial phase of construction with flexibility provided to support a wide range of biopharma projects from early clinical trials through commercial supply production. The facility will also include micro-processing suites for small-scale projects and dedicated suites to support cGMP DNA- and RNA-based biopharmaceutical manufacturing at all phases of development.
Substantial completion of the new facility is targeted for the fourth quarter of 2021 with the initial phase of the facility expected to be operational in the first quarter of 2022.